Literature DB >> 1731098

Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens.

A Penna1, P Fowler, A Bertoletti, S Guilhot, B Moss, R F Margolskee, A Cavalli, A Valli, F Fiaccadori, F V Chisari.   

Abstract

In this study, we show that CD4+, hepatitis B virus (HBV) envelope-specific T-cell clones produced by stimulation with a particulate antigen preparation are able to recognize and kill not only autologous antigen-presenting cells incubated with exogenous HBV envelope antigens but also autologous HLA class II-positive cells expressing endogenously synthesized HBV envelope antigens following infection with recombinant vaccinia viruses or transfection with recombinant Epstein-Barr virus expression vectors. Experiments with lysosomotropic agents and brefeldin A suggest that the endosomal compartment is likely involved in the processing of endogenously synthesized viral proteins for recognition by CD4+ T cells. Our study indicates that HBV envelope-specific, HLA class II-restricted CD4+ cytotoxic T lymphocytes can potentially participate in the immune clearance of HBV-infected cells and the pathogenesis of hepatocellular injury in hepatitis B.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731098      PMCID: PMC240825     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.

Authors:  L Teyton; D O'Sullivan; P W Dickson; V Lotteau; A Sette; P Fink; P A Peterson
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

2.  Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes.

Authors:  V Barnaba; A Franco; A Alberti; R Benvenuto; F Balsano
Journal:  Nature       Date:  1990-05-17       Impact factor: 49.962

3.  MHC class II-restricted presentation of intracellular antigen.

Authors:  S Weiss; B Bogen
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

4.  Ouabain-resistant mutants of the rat Na,K-ATPase alpha 2 isoform identified by using an episomal expression vector.

Authors:  V Canfield; J R Emanuel; N Spickofsky; R Levenson; R F Margolskee
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

5.  Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation.

Authors:  J G Nuchtern; J S Bonifacino; W E Biddison; R D Klausner
Journal:  Nature       Date:  1989-05-18       Impact factor: 49.962

Review 6.  Hepatitis B virus structure and biology.

Authors:  F V Chisari; C Ferrari; M U Mondelli
Journal:  Microb Pathog       Date:  1989-05       Impact factor: 3.738

7.  Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes.

Authors:  J W Yewdell; J R Bennink
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

8.  Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen.

Authors:  C Ferrari; A Bertoletti; A Penna; A Cavalli; A Valli; G Missale; M Pilli; P Fowler; T Giuberti; F V Chisari
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

9.  The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man.

Authors:  C Ferrari; A Penna; A Bertoletti; A Cavalli; A Valli; C Schianchi; F Fiaccadori
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

10.  Selective synthesis and secretion of particles composed of the hepatitis B virus middle surface protein directed by a recombinant vaccinia virus: induction of antibodies to pre-S and S epitopes.

Authors:  K C Cheng; B Moss
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

View more
  13 in total

1.  MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.

Authors:  Martin S Staege; Steven P Lee; Teresa Frisan; Josef Mautner; Siegfried Scholz; Alexander Pajic; Alan B Rickinson; Maria G Masucci; Axel Polack; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

Review 2.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

3.  Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8- cytotoxic T-cell clones.

Authors:  P G Livingston; I Kurane; C J Lai; M Bray; F A Ennis
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

Review 4.  Targeted DNA mutagenesis for the cure of chronic viral infections.

Authors:  Joshua T Schiffer; Martine Aubert; Nicholas D Weber; Esther Mintzer; Daniel Stone; Keith R Jerome
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

5.  Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection.

Authors:  M Lu; G Hilken; J Kruppenbacher; T Kemper; R Schirmbeck; J Reimann; M Roggendorf
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

6.  Strong ability of Nef-specific CD4+ cytotoxic T cells to suppress human immunodeficiency virus type 1 (HIV-1) replication in HIV-1-infected CD4+ T cells and macrophages.

Authors:  Nan Zheng; Mamoru Fujiwara; Takamasa Ueno; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

7.  Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.

Authors:  B T Ober; P Brühl; M Schmidt; V Wieser; W Gritschenberger; S Coulibaly; H Savidis-Dacho; M Gerencer; F G Falkner
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 8.  Hepatitis B virus immunopathology.

Authors:  F V Chisari; C Ferrari
Journal:  Springer Semin Immunopathol       Date:  1995

9.  Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL.

Authors:  Nagendra R Hegde; Claire Dunn; David M Lewinsohn; Michael A Jarvis; Jay A Nelson; David C Johnson
Journal:  J Exp Med       Date:  2005-10-10       Impact factor: 14.307

10.  Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.

Authors:  K Ando; T Moriyama; L G Guidotti; S Wirth; R D Schreiber; H J Schlicht; S N Huang; F V Chisari
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.